This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Calendar: Key Dates for October

BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for October:

Oct. 1-5
Obesity Society annual meeting.

Oct. 3
Onyx Pharmaceuticals (ONXX) v. Bayer flurosorafenib litigation gets underway.

Oct. 5
Research abstracts for the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting made available.

Oct. 6
"Cancer Immunotherapy: A Long-Awaited Reality" conference, sponsored by MD Becker Partners.

Oct. 11-15
American Society for Human Genetics (ASHG) meeting.

Oct. 13
Rigel Pharmaceuticals (RIGL - Get Report) investor/analyst meeting: Asthma strategy and pipeline.

Oct. 19-21
ECTRIMS annual meeting. Key data presentations include Teva's (TEVA) laquinimod and Biogen Idec's (BIIB - Get Report) BG-12.

Oct. 20-23
Infectious Disease Society of America (IDSA) meeting. Dynavax Technologies (DVAX - Get Report) Heplisav Hepatitis B data to be presented.

Oct 22-25
American Academy of Opthalmology (AAO) meeting.

Oct. 24
Amgen (AMGN - Get Report) third-quarter earnings.

Oct. 28
FDA approval decision for Pacira Pharmaceuticals' (PCRX - Get Report) Exparel for post-surgical pain management.
FDA approval decision date for Bristol-Myers Squibb (BMY) and AstraZeneca's (AZN) dapagliflozin for diabetes. An FDA advisory panel on July 19 voted to recommend against approval.

Biotech events expected before the end of September:
Biogen Idec: Top-line results of a phase III study of the multiple sclerosis drug BG-12 compared against Teva's Copaxone.
Exelixis (EXEL): Top-line results of phase III study of cabozantinib in medullary thyroid cancer.

Sources: TheStreet research, company announcements, BioMedTracker

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ONXX $0.00 0.00%
AMGN $156.26 -0.69%
BIIB $396.99 -0.78%
DVAX $22.77 1.16%
EXEL $3.15 0.64%

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs